Hemodynamic and Exercise Effects of Phosphodiesterase 5 Inhibitors
- 1 December 2005
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 96 (12) , 32-36
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Update on Clinical Trials of Tadalafil Demonstrates No Increased Risk of Cardiovascular Adverse EventsThe Journal of Sexual Medicine, 2004
- Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effectsEuropean Heart Journal, 2004
- Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery diseaseThe American Journal of Cardiology, 2004
- Erectile dysfunction: the earliest sign of generalized vascular disease?**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.JACC, 2004
- Therapeutic Potential of Phosphodiesterase 5 Inhibition for Cardiovascular DiseaseCirculation, 2003
- Phosphodiesterase type 5 inhibition in erectile dysfunction: an overviewEuropean Heart Journal Supplements, 2002
- The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemiaJACC, 2002
- Cardiovascular Effects of Sildenafil During Exercise in Men With Known or Probable Coronary Artery DiseaseJAMA, 2002
- Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive menJournal of Human Hypertension, 2001
- Nitric oxide and penile erection: Is erectile dysfunction another manifestation of vascular disease?Cardiovascular Research, 1999